Design, synthesis and evaluation of imidazolylmethyl carbamate prodrugs of alkylating agents

Tetrahedron

Volumn 56, Issue 4, 2000, Pages 645-657

  Hay, Michael P ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antitumour compounds; Carbamates; Imidazoles imidazolines

Indexed keywords

(1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL BIS(2 CHLOROETHYL)CARBAMATE; (1 METHYL 5 NITRO 1H IMIDAZOL 2 YL)METHYL BIS(2 CHLOROETHYL)CARBAMATE; ALKYLATING AGENT; CARBAMIC ACID DERIVATIVE; CARMETHIZOLE; N,N BIS(2 CHLORETHYL)AMINE; PRODRUG; UNCLASSIFIED DRUG; [1 METHYL 5 (METHYLSULFINYL) 1H IMIDAZOL 2 YL]METHYL BIS(2 CHLOROETHYL)CARBAMATE; [2 AZIDO 1 METHYL 4 [[[(METHYLAMINO)CARBONYL]OXY]METHYL] 1H IMIDAZOL 5 YL]METHYL METHYL CARBAMATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MURINAE; OXY;

EID: 0034695519     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)01031-5     Document Type: Article

References (57)

1. Denny W.A., Wilson W.R. J. Pharm. Pharmacol. 50:1998;387-394.
2. Denny W.A. Curr. Pharm. Des. 2:1996;281-294.
3. Sinhababu A.K., Thakker D.R. Adv. Drug Delivery Rev. 19:1996;241-273.
4. Jungheim L.N., Shepherd T.A. Chem. Rev. 94:1994;1553-1556.
5. Hay M.P., Denny W.A. Drugs Future. 21:1996;917-931.
6. Melton R.G., Sherwood R.F. J. Natl. Cancer Inst. 88:1996;153-165.
7. Huber B.E., Richards C.A., Austin E.A. Adv. Drug Delivery Rev. 17:1995;279-292.
8. Niculescu-Duvaz I., Spooner R., Marais R., Springer C.J. Bioconjugate Chem. 9:1998;4-22.
9. Denny W.A., Wilson W.R., Hay M.P. Br. J. Cancer. 74:1996;S32-S38.
10. Stratford I.J., Workman P. Anti-Cancer Drug Des. 13:1998;519-528.
11. Chapman J.D. Radiother. Oncol. 20:(S1):1991;13-19.
12. Chaplin D.J., Durand R.E., Olive P.L., Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1279-1282.
13. Chaplin D.J., Olive P.L., Durand R.E. Cancer Res. 47:1987;597-601.
14. Vaupel P., Kallinowski F., Okunieff P. Cancer Res. 49:1989;6449-6465.
15. Wilson W.R. Waring M.J., Ponder B.A.J. Tumour Hypoxia: Challenges for Cancer Chemotherapy. Cancer Biology and Medicine. 3:1992;87-131 Kluwer Academic Publishers, Lancaster.
16. Anderson W.K., Bhattacharjee D., Houston M.D. J. Med. Chem. 32:1989;119-127.
17. Elliot W.L., Fry D.W., Anderson W.K., Nelson J.M., Hook K.E., Hawkins P.A., Leopold W.R. III. Cancer Res. 51:1991;4581-4587.
18. Waud W.R., Plowman J., Harrison S.D. Jr., Dykes D.J., Anderson W.K., Griswold D.P. Jr. Cancer Chemother. Pharmacol. 30:1992;261-266.
19. Jarosinski M.A., Reddy P.S., Anderson W.K. J. Med. Chem. 36:1993;3618-3627.
20. A preliminary report of part of this work has been published, Hay, M. P.; Denny, W. A. Tetrahedron Lett. 1997, 38, 8425-8428.
21. Hansch C., Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. 1979;49 Wiley, New York.
22. 2Me used as an approximation.
23. Scriven E.F.V., Turnbull K. Chem. Rev. 88:1988;297-368.
24. Nicholls D., Gescher A., Griffin R.J. Xenobiotica. 21:1991;935-943.
25. Bliss E.A., Brown T.B., Stevens M.F.G., Wong C.K. J. Pharm. Pharmacol. 31:(S):1979;66.
26. Stevens M.F.G., Griffin R.J., Wong S.K. Anti-Cancer Drug Des. 2:1987;311-318.
27. Denny W.A., Wilson W.R. J. Med. Chem. 29:1986;879-887.
28. Alvaro R.F., Wislocki P.G., Miwa G.T., Lu A.Y.H. Chem.-Biol. Interact. 82:1992;21-30. and references therein.
29. Prakash, S. R.; Correa, I. D.; Gan, L.-S.; Chism, J. P.; Arrendale, R. F.; Miwa, G. T.; Thakker, D. R. In Synth. Appl. Isot. Labelled Compd., Proceedings of the Fifth International Symposium, 1994; Allen, J., Voges, R., Eds.; Wiley: Chichester, UK, 1995; pp 573-576.
30. Everett S.A., Naylor M.A., Patel K.B., Stratford M.R.L., Wardman P. Bioorg. Med. Chem. Lett. 9:1999;1267-1272.
31. Anderson R.F., Denny W.A., Li W., Packer J.E., Tercel M., Wilson W.R. J. Phys. Chem. 101:1997;9704-9709.
32. Wilson W.R., Ferry D.M., Tercel M., Anderson R.F., Denny W.A. Radiat. Res. 149:1998;237-246.
33. Lee S.C., Renwick A.G. Biochem. Pharmacol. 49:1995;1557-1565.
34. Duggan D.E. Drug Metab. Rev. 12:1981;325-337.
35. Davies N.M., Watson M.S. Clin. Pharmacokinet. 32:1997;437-459.
36. Doering W.von E., DePuy C.H. J. Am. Chem. Soc. 75:1953;5955.
37. Koziara A., Zwierzak A. Synthesis. 1992;1063-1065.
38. Schmidt U., Geiger F. Ann. Chem. 664:1963;168-188.
39. Cavalleri B., Ballotta R., Lancini G.C. J. Heterocycl. Chem. 9:1972;979-984.
40. Sharma R., Voynov G.H., Ovaska T.V., Marquez V.E. Synlett. 1995;839-840.
41. Iddon B., Ngochindo R.I. Heterocycles. 38:1994;2487-2568.
42. Hazeldine C.E., Pyman F.L., Winchester J. J. Chem. Soc. 1924;1431-1441.
43. Compound 8 is noted in Refs. 3 and 28 but no detail is provided.
44. Wilson W.R., Thompson L.H., Anderson R.F., Denny W.A. J. Med. Chem. 32:1989;31-38.
45. Hoy C.A., Thompson L.H., Mooney C.L., Salazar E.P. Cancer Res. 45:1985;1737-1743.
46. Hoy C.A., Salazar E.P., Thompson L.H. Mutat. Res. 130:1984;321-332.
47. Born J.L., Smith B.R., Harper N., Koch C.J. Biochem. Pharmacol. 43:1992;1337-1344. and references therein.
48. Brezden C.B., McClelland R.A., Rauth A.M. Biochem. Pharmacol. 48:1994;361-370. and references therein.
49. Hay M.P., Sykes B.M., Denny W.A., Wilson W.R. Bioorg. Med. Chem. Lett. 9:1999;2237-2242.
50. Bauer L., Namburg C.N.V., Dhauran D. J. Heterocycl. Chem. 1:1964;275-278.
51. O'Connell J.F., Parquette J., Yelle W.E., Wang W., Rappoport H. Synthesis. 1988;767-771.
52. Cavalleri B., Ballotta R., Arioli V., Lancini G.C. J. Med. Chem. 16:1973;557-560.
53. Iverson P.E., Lund H. Acta Chem. Scand. 20:1966;2649-2657.
54. Adebayo A.T., Bowman W.R., Salt W.G. J. Chem. Soc., Perkin Trans. 1. 1987;2819-2827.
55. Rufer C., Kessler H.-J., Schroder E. J. Med. Chem. 14:1971;94-96.
56. Finlay G.J., Baguley B.C., Wilson W.R. Anal. Biochem. 139:1984;272-277.
57. Siim B.G., Atwell G.J., Wilson W.R. Br. J. Cancer. 70:1994;596-603.